Tennant Phil 4

What Happened
Phil Tennant, Chief Commercial Officer of Precigen, received equity awards on April 20, 2026: 385,000 derivative option awards and 115,000 restricted stock units (RSUs). Both grants were reported at a $0.00 price on the Form 4 (total 500,000 awarded units). These were awards (code A) rather than open-market purchases or sales — they vest over multi-year schedules and are not immediately tradable shares.

Key Details

• Transaction date: April 20, 2026; Form 4 filed April 22, 2026 (timely filing).
• Grants: 385,000 options @ $0.00 (derivative) and 115,000 RSUs @ $0.00 (derivative). Form reports $0 value for the grants.
• Vesting (options): 25% vests May 23, 2027, then equal monthly installments over the following three years (footnote F1).
• RSU details: each RSU equals a contingent right to one share (footnote F2). RSUs vest 25% on May 23, 2027 and then in equal six‑month installments over the next three years (footnote F3).
• Shares owned after transaction: not provided in the extracted data — see the full Form 4 for total beneficial ownership.
• Filing timeliness: filed within two days of the report date; no late filing indicated.

Context

• These awards are long‑term compensation tied to continued service and performance via vesting schedules; they do not represent an immediate market purchase or sale.
• Options and RSUs can create future share dilution if and when RSUs settle or options are exercised and shares are issued.
• For full details (total holdings, grant terms, potential exercise prices, and dilution), consult the complete Form 4 and company disclosures.